Garry G Graham

Summary

Affiliation: St Vincent's Hospital
Country: Australia

Publications

  1. ncbi request reprint [Tolerability of paracetamol]
    Garry G Graham
    Departement de Pharmacologie Clinique, Hôpital Saint Vincent et Ecole des Sciences médicales, Université de Nouvelle Galles du Sud, Sydney, Australie
    Drugs 63:43-6. 2003
  2. doi request reprint Acetaminophen (paracetamol) inhibits myeloperoxidase-catalyzed oxidant production and biological damage at therapeutically achievable concentrations
    Maud Koelsch
    Heart Research Institute, Newtown, Sydney, NSW, Australia
    Biochem Pharmacol 79:1156-64. 2010
  3. ncbi request reprint Mechanism of action of paracetamol
    Garry G Graham
    Department of Physiology and Pharmacology, University of New South Wales, St Vincent s Hospital, Darlinghurst, NSW 2010, Australia
    Am J Ther 12:46-55. 2005
  4. ncbi request reprint Tolerability of paracetamol
    Garry G Graham
    Department of Clinical Pharmacology, St Vincent s Hospital, School of Medical Sciences, Sydney, Australia
    Drug Saf 28:227-40. 2005
  5. doi request reprint Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout
    Sophie L Stocker
    Department of Clinical Pharmacology, St Vincent s Hospital, NSW 2010, Sydney, Australia
    J Rheumatol 38:904-10. 2011
  6. pmc Understanding the dose-response relationship of allopurinol: predicting the optimal dosage
    Garry G Graham
    Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, NSW, Australia School of Medical Sciences, University of New South Wales, NSW, Australia
    Br J Clin Pharmacol 76:932-8. 2013
  7. doi request reprint Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers
    Daniel Y Ng
    Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, Xavier Level 2, Darlinghurst, NSW 2010, Australia
    Eur J Clin Pharmacol 67:709-13. 2011
  8. doi request reprint Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function
    Janna K Duong
    School of Medical Sciences, University of New South Wales, Kensington, Sydney, NSW, Australia
    Clin Pharmacokinet 52:373-84. 2013
  9. doi request reprint An audit of a therapeutic drug monitoring service for allopurinol therapy
    Diluk R W Kannangara
    Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital School of Medical Sciences, University of New South Wales Department of Chemical Pathology, St Vincent s Hospital and St Vincent s Clinical School, University of New South Wales, Sydney, Australia
    Ther Drug Monit 35:863-6. 2013
  10. doi request reprint The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings
    Garry G Graham
    Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, University of New South Wales, Sydney, Australia
    Inflammopharmacology 21:201-32. 2013

Collaborators

Detail Information

Publications24

  1. ncbi request reprint [Tolerability of paracetamol]
    Garry G Graham
    Departement de Pharmacologie Clinique, Hôpital Saint Vincent et Ecole des Sciences médicales, Université de Nouvelle Galles du Sud, Sydney, Australie
    Drugs 63:43-6. 2003
    ..Despite the conversion of paracetamol to reactive compounds, hypersensitivity reactions are rare, although urticaria is produced in occasional patients...
  2. doi request reprint Acetaminophen (paracetamol) inhibits myeloperoxidase-catalyzed oxidant production and biological damage at therapeutically achievable concentrations
    Maud Koelsch
    Heart Research Institute, Newtown, Sydney, NSW, Australia
    Biochem Pharmacol 79:1156-64. 2010
    ..Overall, these data indicate that acetaminophen may be an important modulator of MPO activity in vivo...
  3. ncbi request reprint Mechanism of action of paracetamol
    Garry G Graham
    Department of Physiology and Pharmacology, University of New South Wales, St Vincent s Hospital, Darlinghurst, NSW 2010, Australia
    Am J Ther 12:46-55. 2005
    ..The action of paracetamol at a molecular level is unclear but could be related to the production of reactive metabolites by the peroxidase function of COX-2, which could deplete glutathione, a cofactor of enzymes such as PGE synthase...
  4. ncbi request reprint Tolerability of paracetamol
    Garry G Graham
    Department of Clinical Pharmacology, St Vincent s Hospital, School of Medical Sciences, Sydney, Australia
    Drug Saf 28:227-40. 2005
    ..Paracetamol appears to be well tolerated during pregnancy although prospective studies are required...
  5. doi request reprint Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout
    Sophie L Stocker
    Department of Clinical Pharmacology, St Vincent s Hospital, NSW 2010, Sydney, Australia
    J Rheumatol 38:904-10. 2011
    ..To investigate the pharmacokinetic and pharmacodynamic interaction between probenecid and oxypurinol (the active metabolite of allopurinol) in patients with gout...
  6. pmc Understanding the dose-response relationship of allopurinol: predicting the optimal dosage
    Garry G Graham
    Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, NSW, Australia School of Medical Sciences, University of New South Wales, NSW, Australia
    Br J Clin Pharmacol 76:932-8. 2013
    ..The aim of the study was to identify and quantify factors that control the plasma concentrations of urate during allopurinol treatment and to predict optimal doses of allopurinol...
  7. doi request reprint Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers
    Daniel Y Ng
    Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, Xavier Level 2, Darlinghurst, NSW 2010, Australia
    Eur J Clin Pharmacol 67:709-13. 2011
    ..To determine whether low-dose aspirin and hydrochlorothiazide (HCTZ) affect the renal clearance of oxypurinol and/or urate...
  8. doi request reprint Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function
    Janna K Duong
    School of Medical Sciences, University of New South Wales, Kensington, Sydney, NSW, Australia
    Clin Pharmacokinet 52:373-84. 2013
    ....
  9. doi request reprint An audit of a therapeutic drug monitoring service for allopurinol therapy
    Diluk R W Kannangara
    Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital School of Medical Sciences, University of New South Wales Department of Chemical Pathology, St Vincent s Hospital and St Vincent s Clinical School, University of New South Wales, Sydney, Australia
    Ther Drug Monit 35:863-6. 2013
    ....
  10. doi request reprint The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings
    Garry G Graham
    Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, University of New South Wales, Sydney, Australia
    Inflammopharmacology 21:201-32. 2013
    ..There is considerable debate about the hepatotoxicity of therapeutic doses of paracetamol. Much of the toxicity may result from overuse of combinations of paracetamol with opioids which are widely used, particularly in USA...
  11. ncbi request reprint Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects
    Sophie L Stocker
    Faculty of Pharmacy, University of Sydney, Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, Sydney, New South Wales, Australia
    Clin Pharmacokinet 47:111-8. 2008
    ..The objective of this study was to investigate the pharmacokinetics and hypouricaemic effect of oxypurinol (the active metabolite of allopurinol) and probenecid when administered alone and in combination in healthy subjects...
  12. ncbi request reprint Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012
    Sheena N Ramasamy
    Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, 390 Victoria Street, Darlinghurst, NSW, 2010, Australia
    Drug Saf 36:953-80. 2013
    ..Severe forms of AH have been associated with high mortality. The pathophysiology underlying this reaction remains unknown, but several risk factors have been proposed...
  13. pmc The pharmacokinetics of oxypurinol in people with gout
    Sophie L Stocker
    Faculty of Pharmacy, University of Sydney, NSW, Australia
    Br J Clin Pharmacol 74:477-89. 2012
    ..Our aim was to identify and quantify the sources of variability in oxypurinol pharmacokinetics and explore relationships with plasma urate concentrations...
  14. doi request reprint Optimizing therapy with allopurinol: factors limiting hypouricemic efficacy
    Yewon Chung
    Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, Sydney, Australia
    Am J Med Sci 335:219-26. 2008
    ..Probenecid increases the hypouricemic effect of allopurinol but the favorable interaction may be significant only in patients with glomerular filtration rates greater than about 50 mL/min...
  15. pmc A proposal for identifying the low renal uric acid clearance phenotype
    Praveen L Indraratna
    Faculty of Medicine, University of New South Wales, NSW, 2052, Australia
    Arthritis Res Ther 12:149. 2010
    ..We also propose that a single daytime spot urine sample for calculation of fractional renal clearance of urate should be preferred to calculation from 24-hour urine collections...
  16. ncbi request reprint Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol)
    Garry G Graham
    Department of Physiology and Pharmacology, School of Medical Sciences, Faculty of Medicine, Sydney, 2052, Australia
    Curr Pharm Des 8:1063-75. 2002
    ..No such associations have been made with acetaminophen, possibly because it is a weak inhibitor of COX-1 in platelets...
  17. doi request reprint FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?
    Garry G Graham
    Department of Clinical Pharmacology, St Vincent s Hospital, Darlinghurst, NSW, 2010, Australia
    Inflammopharmacology 18:47-55. 2010
    ..Adoption of these two recommendations may lead to the increased use of NSAIDs with the potential of increasing incidence of NSAIDs-related adverse reactions...
  18. doi request reprint Antifungal use and therapeutic monitoring of plasma concentrations of itraconazole in heart and lung transplantation patients
    Jonathan Brett
    Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, Darlinghurst, New South Wales, Australia
    Ther Drug Monit 35:133-6. 2013
    ..To further reduce this incidence, it has been suggested that plasma concentrations of itraconazole be monitored and maintained above a putative minimum target concentration of 500 ng/mL...
  19. ncbi request reprint A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?
    Ming Han H Lee
    Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, University of New South Wales, Sydney, New South Wales, Australia
    Drug Saf 31:643-65. 2008
    ..We conclude that the withdrawal of benzbromarone was not in the best interest of patients with gout...
  20. doi request reprint Clinical pharmacokinetics of metformin
    Garry G Graham
    Department of Pharmacology and Toxicology, St Vincents Clinical School, University of New South Wales, Sydney, New South Wales, Australia
    Clin Pharmacokinet 50:81-98. 2011
    ..We suggest that the mean plasma concentrations of metformin over a dosage interval be maintained below 2.5 mg/L in order to minimize the development of this adverse effect...
  21. ncbi request reprint Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol
    Richard O Day
    School of Medical Sciences, Faculty of Medicine, University of New South Wales and Department of Clinical Pharmacology and Toxicology, St Vincent s Hospital, Sydney, New South Wales, Australia
    Clin Pharmacokinet 46:623-44. 2007
    ..The net effect is an increased degree of hypouricaemia, but the interaction is probably limited to patients with normal renal function or only moderate impairment...
  22. ncbi request reprint Secreted phospholipase A2 enzymes as therapeutic targets
    Kieran F Scott
    St Vincent s Hospital Clinical School, School of Medical Sciences, The University of New South Wales, Sydney, Australia
    Expert Opin Ther Targets 7:427-40. 2003
    ....
  23. ncbi request reprint Emerging roles for phospholipase A2 enzymes in cancer
    Kieran F Scott
    St Vincent s Hospital Clinical School, The University of New South Wales, L5 DeLacey Bldg, St Vincent s Hospital, Darlinghurst NSW 2010, Australia
    Biochimie 92:601-10. 2010
    ....
  24. ncbi request reprint Paracetamol should be first-line therapy in osteoarthritis
    Richard O Day
    Med J Aust 182:198-9; author reply 199. 2005